On ECHEMI
Home > Drugs > Changchun Lnstitute of Biological Products Co., Ltd.
Changchun Lnstitute of Biological Products Co., Ltd.
  • Founded in:

    1985-12-05
  • Country:

    China China
  • Address:

    No. 1616, Chuangxin Road, Changchun High-tech Development Zone (Production and operation location: No. 285, Chaoran Street, Changchun High-tech Development Zone)
  • Tax NO.:

    91220101123998130E
  • Registered Funds:

    2,094.3041 million yuan
  • Website:

  • Email:

Related Drugs
Influenza virus split vaccine
The composition of this vaccine is in line with the strains recommended by WHO for the current year. Each dose of vaccine contains three strains of antigens: type A1, type A3, and type B. Type A1 (New Caledonia/20/99 (H1N1) reassortant [IVR-116 strain]) Hemagglutinin content: ge; 12mu; g Type A3 (Fujian/41I/02 (H3N2) similar strain [NYMCX-147 strain]) Hemagglutinin content: ge; 12mu; g Type B (B/Shanghai/36I/02 similar strain [B/Jiangsu/10/2003 strain]) Hemagglutinin content: ge; 12mu; g
Name Description Content CAS NO. Registered Holders
Type A1 (New Caledonia/20/99 (H1N1) reassortant [IVR-116 strain])

Split-type vaccines stimulate the body to produce immunity to prevent influenza viruses. Immunity is produced 10-15 days after vaccination and lasts for more than 1 year

More

Split-type vaccines stimulate the body to produce immunity to prevent influenza viruses. Immunity is produced 10-15 days after vaccination and lasts for more than 1 year

12mcg 0
Type A3 (Fujian/41I/02(H3N2) similar strain [NYMCX-147 strain])

Split-type vaccines stimulate the body to produce immunity to prevent influenza viruses. Immunity is produced 10-15 days after vaccination and lasts for more than 1 year

More

Split-type vaccines stimulate the body to produce immunity to prevent influenza viruses. Immunity is produced 10-15 days after vaccination and lasts for more than 1 year

12mcg 0
Type B (similar strains of B/Shanghai/36I/02 [B/Jiangsu/10/2003])

Split-type vaccines stimulate the body to produce immunity to prevent influenza viruses. Immunity is produced 10-15 days after vaccination and lasts for more than 1 year

More

Split-type vaccines stimulate the body to produce immunity to prevent influenza viruses. Immunity is produced 10-15 days after vaccination and lasts for more than 1 year

12mcg 0
Recombinant human interleukin-2 for injection
Name Description Content CAS NO. Registered Holders
Recombinant human interleukin-2

Extract from the above information

More

Extract from the above information

0
Recombinant human interleukin-2 for injection
Main ingredients: recombinant human interleukin-2, derived from recombinant Escherichia coli; auxiliary materials: human albumin.
Name Description Content CAS NO. Registered Holders
Recombinant human interleukin-2

It is a lymphokine that can cause cytotoxic T cells, natural killer cells and lymphokine-activated killer cells to proliferate and enhance their killing activity. It can also induce lymphocytes to secrete antibodies and interferon. It has antiviral, anti-tumor and immune-enhancing effects.

More

It is a lymphokine that can cause cytotoxic T cells, natural killer cells and lymphokine-activated killer cells to proliferate and enhance their killing activity. It can also induce lymphocytes to secrete antibodies and interferon. It has antiviral, anti-tumor and immune-enhancing effects.

0
Recombinant human interleukin-2 for injection
Main ingredients: recombinant human interleukin-2, derived from recombinant Escherichia coli; auxiliary materials: human albumin.
Name Description Content CAS NO. Registered Holders
Recombinant human interleukin-2

It is a lymphokine that can cause cytotoxic T cells, natural killer cells and lymphokine-activated killer cells to proliferate and enhance their killing activity. It can also induce lymphocytes to secrete antibodies and interferon. It has antiviral, anti-tumor and immune-enhancing effects.

More

It is a lymphokine that can cause cytotoxic T cells, natural killer cells and lymphokine-activated killer cells to proliferate and enhance their killing activity. It can also induce lymphocytes to secrete antibodies and interferon. It has antiviral, anti-tumor and immune-enhancing effects.

0
Recombinant human interleukin-2 for injection
Main ingredients: recombinant human interleukin-2, derived from recombinant Escherichia coli; auxiliary materials: human albumin.
Name Description Content CAS NO. Registered Holders
Recombinant human interleukin-2

It can cause the proliferation of cytotoxic T cells, natural killer cells and lymphokine-activated killer cells and enhance their killing activity. It can also induce lymphocytes to secrete antibodies and interferon. It has anti-viral, anti-tumor and immune-enhancing effects.

More

It can cause the proliferation of cytotoxic T cells, natural killer cells and lymphokine-activated killer cells and enhance their killing activity. It can also induce lymphocytes to secrete antibodies and interferon. It has anti-viral, anti-tumor and immune-enhancing effects.

0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.